Assessing the Value for Money of Vaccine Product Development Partnerships

2012; United States; International AIDS Vaccine Initiative

The International AIDS Vaccine Initiative (IAVI) is a global not for profit organisation whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996, IAVI works with partners in 25 countries to research, design and develop AIDS vaccine candidates. IAVI also conducts policy analysis and serves as an advocate for the AIDS vaccine field.

This assignment saw Itad supporting IAVI in developing a framework for assessing the ‘value for money’ (VFM) generated through vaccine-focused Product Development Partnerships (PDPs), and making recommendations on improving the measurement and reporting of VFM. While several evaluation frameworks exist for PDPs there is no consensus on how to assess the VFM of PDPs, particularly given that PDPs operate in distinct disease and product areas, and use distinct operating models.

Itad mobilised a 5-person team of international consultants with a mix of skills in VFM analysis, Product Development Partnerships, HIV/AIDS Programming, and Monitoring & Evaluation (M&E). In the first phase of this assignment, the team carried out an assessment of current VFM models that had been developed by other research and development organisations and reviewed existing VFM frameworks developed in the UK context. IAVI’s current M&E Framework was also reviewed and the Itad team worked with IAVI staff to develop a Theory of Change at a workshop with senior staff. In the second phase of this work (ongoing) Itad are working with IAVI to run a comprehensive ‘VFM Diagnostic’ of the existing indicators and help make comprehensive recommendations for improving their VFM measurement and reporting.

Image © Washing.  

For more information please contact:

Sam McPherson
Email
LinkedIn
T: +44(0)1273 765250